Cargando…
Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds
The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein–protein interactions. We have refined crystallization conditions for KRAS(169)(Q61H)-yielding crystals suitable for soaking...
Autores principales: | Cruz-Migoni, Abimael, Canning, Peter, Quevedo, Camilo E., Bataille, Carole J. R., Bery, Nicolas, Miller, Ami, Russell, Angela J., Phillips, Simon E. V., Carr, Stephen B., Rabbitts, Terence H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377466/ https://www.ncbi.nlm.nih.gov/pubmed/30683716 http://dx.doi.org/10.1073/pnas.1811360116 |
Ejemplares similares
-
BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
por: Bery, Nicolas, et al.
Publicado: (2018) -
Correction: BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
por: Bery, Nicolas, et al.
Publicado: (2018) -
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
por: Quevedo, Camilo E., et al.
Publicado: (2018) -
Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds
por: Canning, Peter, et al.
Publicado: (2021) -
Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody
por: Tanaka, Tomoyuki, et al.
Publicado: (2021)